Cartesian Therapeutics vs Upstream Bio
Upstream Bio reported revenue of $3 million in fiscal 2025, about the same as Cartesian Therapeutics' $3 million in fiscal 2025. Cartesian Therapeutics' revenue fell 92.8% in its latest year, and Upstream Bio's grew 20.4%. Cartesian Therapeutics had an operating margin of -5127.1%, against -5618.8% at Upstream Bio. Free cash flow was −$79 million at Cartesian Therapeutics and −$133 million at Upstream Bio.
Side by side
| Cartesian Therapeutics | Upstream Bio | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $3M | $3M |
| Revenue growth | −92.8% | 20.4% |
| Revenue growth a year, last 5 years | −29.9% | — |
| Gross margin | — | — |
| Operating margin | −5,127.1% | −5,618.8% |
| Net margin | −4,658.6% | −5,026.0% |
| Free cash flow | −$79M | −$133M |
| Free cash flow margin | −2,838.6% | −4,675.5% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 49.6% | 293.6% |
| Last close | $5.89 | $2.00 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $205,800, sold $258,683 | sold $104,799 |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Cartesian TherapeuticsUpstream Bio
Operating margin
Percent of revenue
Cartesian TherapeuticsUpstream Bio
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Cartesian TherapeuticsUpstream Bio
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Cartesian Therapeutics and Upstream Bio pages.